Annual report and accounts 30 June 2007 Abcam plc 01 Highlights Sales increased 26.6% to 24.5m 2006: 19.4m, representing a 33.8% increase using constant exchange % rates.
26.6 Sales increased 26.6% to 24.5 million Pre-tax profits increased 18.1% to 5.7m 2006: 4.8m.
Product range grew to 33,900 antibodies and related products 2006: 23,200.
Three licensing deals agreed giving Abcam exclusive distribution rights to over 4,000 existing and future complementary products.
High-throughput production HTP laboratory built to boost the number of high-margin in-house products.
M Operations began on schedule and the first antibodies 5.7 will be ready for sale later this calendar year.
Profit before tax of 5.7 million in the year New subsidiary in Tokyo trading well to help Abcam further develop its fast-growing Asia-Pacific business.
Net cash and short term investments at 30 June 2007 of 10.7m 2006: 11.9m.
Dividend policy increased from 25% to 33% of profit after tax.
Final dividend up 60% to 3.19p per share 2006: 2.0p.
